OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Cellular and gene therapy fields are currently on track for a serious capacity crunch.
CDMOs adopt flexible processes for manufacturing investigational drug products.
Outsourcing companies fill the gap in drug development and manufacturing.
January 11, 2021
A strategic separation is designed to enhance the value and growth of Paraxel’s contract research services and Calyx’s imaging businesses.
January 06, 2021
Vendors are finding ways to address the increasingly complex analytical challenges in the biopharmaceutical industry to further biotherapeutic development.
January 02, 2021
After a hectic 2020, biopharma looks to deliver on COVID-19 vaccines and move other promising therapies forward.
January 01, 2021
Outsourcing increases as the industry balances development and manufacturing of both COVID-19 treatments and non-pandemic-related medicines.
December 10, 2020
Evonik offers lipid nanoparticles for gene-based drug development and manufacturing.
December 09, 2020
The company is investing in expansion at four sites in the United States, United Kingdom, and Italy, which will include construction of new facilities and addition of sterile and lyophilized filling lines.
Cytiva is adding process development, media and assay development, and contract development services at its facilities in Korea, Japan, Sweden, and the UK.
December 01, 2020
CDMOs strive for flexible, adaptable processes and fast tech transfer for manufacturing investigational drug products, including COVID-19 treatments and vaccines
November 23, 2020
The new super plant, being built in Incheon, South Korea, will have a total biopharmaceutical manufacturing capacity of 256,000 L.
The companies have formed a long-term manufacturing agreement to accelerate the global supply for Lilly’s COVID-19 antibody therapeutics.